388 results about "Phenylalanine" patented technology

The present invention belongs to the technical field of biological prevention and treatment for viral diseases. Disclosed in the present invention are a tomato disease-resistant gene mutant, and the use thereof in the prevention and treatment of ToBRFV. It is found in the present invention that mutating the nucleotide at position 1927 of the coding region sequence of tomato Tm-22 gene from G to A, or mutating the amino acid at position 643 of the LRR domain of a protein that is encoded by tomato Tm-22 gene from glycine to arginine can remarkably reduce the accumulation level of ToBRFV capsid protein (CP). The gene (named Tm-22-Mut5) can serve as a novel ToBRFV resistant gene, and also retains the resistance to TMV, ToMV and ToMMV. The Tm-22-Mut5 and a pre-screened Tm-22-Mut3-1 mutant (tyrosine at position 767 of the LRR domain thereof is mutated to phenylalanine) undergo combinatorial mutagenesis to obtain a mutant Tm-22-Mut6. Analysis shows that the Tm-22-Mut6 can remarkably reduce the accumulation level of the ToBRFV capsid protein. Compared with the pFGCTm-22-Mut3-1 mutant obtained by screening in the previous research and the newly obtained mutant Tm-22-Mut5, the Tm-22-Mut6 has further improved resistance to ToBRFV.

The invention belongs to the technical field of bioengineering, and relates to a transaminase mutant, a recombinant genetically engineered bacterium and application of the transaminase mutant in catalytic synthesis of (R)-1-Boc-3-aminopiperidine.The transaminase mutant is obtained by conducting single-point or combined mutation on the 131 site and / or the 197 site of an amino acid sequence shown in SEQ ID NO.2; the mutation sites comprise that the 131 phenylalanine is mutated into aspartic acid, threonine or tyrosine, and / or the 197 lysine is mutated into arginine or leucine. Experimental results show that compared with wild type transaminase, the catalytic activity, the thermal stability and the organic solvent tolerance of the obtained mutants, especially single-point mutants MyTA1-F131Y and MyTA1-K197R and a combined mutant MyTA1-F131Y-K197R, are all remarkably improved, and compared with the wild type transaminase, the catalytic activity, the thermal stability and the organic solvent tolerance of the obtained mutants are all remarkably improved. The mutant MyTA1-F131Y-K197R can be used for efficiently catalyzing asymmetric amination of N-Boc-3-piperidone to synthesize (R)-1-Boc-3-aminopiperidine, the conversion rate of the (R)-1-Boc-3-aminopiperidine after the (R)-1-Boc-3-aminopiperidine reacts for 24 hours under the condition that the substrate concentration is 100 g / L can reach 90% or above, and the mutant MyTA1-F131Y-K197R has a good industrial application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine in evaluating Kawasaki disease and treating effect thereof and application of a phenylalanine inhibitor in treating Kawasaki disease. According to serum non-targeted metabonomics analysis and verification of KD children and IVIG treated KD children, phenylalanine is highly expressed in KD children, and phenylalanine is remarkably reduced after IVIG treatment of KD and tends to healthy children. The phenylalanine can be used as a serological marker for evaluating the Kawasaki disease treatment effect and diagnosing IVIG second-line treatment, and is high in specificity and sensitivity. After the phenylalanine inhibitor is administered to a KD model mouse, the content of phenylalanine in serum is remarkably reduced and is consistent with the trend in serum of the KD mouse treated by IVIG, myrica tongues are remarkably relieved, arterial dilatation is slowed down, and expression of inflammatory factors is reduced. The phenylalanine inhibitor has the effects of treating Kawasaki disease, improving myrica rubra tongue and slowing down arterial dilatation.

The application discloses a kind of nano magnetic flocculants and its preparation method and application, belong to drinking water processing technical field, including the following steps: step S1, modified ferroferric oxide nanosphere is ultrasonically dispersed in ammonia alcohol solution, while stirring, slowly drop adding tetraethyl orthosilicate, continue stirring after drop, after centrifugal separation, wash, obtain silica coated ferroferric oxide nanoparticles;Step S2, phenylalanine modified chitosan is added into glacial acetic acid solution, after completely swelling and dissolving, add silica coated ferroferric oxide nanoparticles and ultrasonic treatment, under low pressure ultraviolet lamp, then with anhydrous ethanol wash purification, vacuum drying to constant weight, obtain nano magnetic flocculants;The method of the application is simple and easy to operate, the nano magnetic flocculants prepared can be quickly adsorbed to the surface of sulfonamide antibiotics, produce flocculation and can be magnetically separated, very suitable for trace sulfonamide antibiotics in drinking water source efficient removal.

The invention discloses an amino acid composition for treating alopecia and application of the amino acid composition in preparation of a medicine for treating alopecia, and belongs to the field of medicine configuration products, the amino acid composition is composed of a targeting core intervention component and an auxiliary strengthening synergistic component, the targeting core intervention component is prepared from 30-50 parts of arginine, 50-155 parts of lysine and 50-120 parts of glutamic acid, and the auxiliary strengthening synergistic component is prepared from an auxiliary strengthening synergistic component and an auxiliary strengthening synergistic component. 10 to 40 parts of cysteine and 20 to 60 parts of leucine; the auxiliary strengthening synergistic component is prepared from 15 to 45 parts of tyrosine, 15 to 40 parts of glycine, 10 to 40 parts of glutamine, 20 to 35 parts of serine, 5 to 25 parts of alanine, 2 to 20 parts of aspartic acid and 15 to 35 parts of phenylalanine; the composition can be used as an active ingredient to be prepared into different dosage forms such as a pigmentum, a spray, an ointment and a liniment, is applied to prevention of alopecia and promotion of hair growth, and has a remarkable treatment effect.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention relates to the technical field of biological catalysis, and discloses an M88F mutant enzyme for preparing rebaudioside I. The enzyme is obtained by the following mutations generated by UGT76G1: M88F: methionine of the 88th amino acid sequence of UGT76G1 is mutated into phenylalanine; and the substrate rebaudioside A (RA) can be efficiently and directionally converted into rebaudioside I (RI) with higher value. In an optimized reaction system, the conversion rate stably reaches 40%, and the catalytic efficiency is improved by more than 5-8 times compared with the common reference enzyme. The enzyme preparation has the characteristics of high catalytic activity, mild reaction conditions, simplicity and convenience in operation and the like, shows good stability and reproducibility in laboratory research and large-scale production, and has a wide industrial application prospect.

A gene editing protein variant is capable of reducing a gene editing off-target rate. The variant is an unnatural protein with cis-cleavage activity, and the variant has reduced trans-cleavage activity as compared to a wild-type gene editing protein thereof. Furthermore, the variant is mutated at one or more of cleavage activity-related core amino acid sites of the wild-type gene editing protein selected from the following: a phenylalanine (F) site corresponding to the 1081st position of FnCas12a; and / or a lysine (K) site corresponding to the 1069th site of the FnCas12a. The variant can have cis-cleavage activity and reduced trans-cleavage activity. Moreover, the gene editing protein variant or a gene editing system having the gene editing protein variant can significantly reduce the gene editing off-target rate.

The invention discloses a salicylic acid decarboxylase mutant and application of the salicylic acid decarboxylase mutant in degradation of salicylic acid. The mutant is obtained by carrying out site-specific modification on salicylic acid decarboxylase NahG, and specifically, valine at the 46th site, tyrosine at the 380th site and leucine at the 382nd site of an amino acid sequence shown in SEQ ID NO.2 are mutated into cysteine, phenylalanine and phenylalanine at the same time. The mutant shows remarkably improved catalytic efficiency, and salicylic acid can be efficiently and thoroughly decarboxylated and converted into catechol under mild conditions. The invention also provides a coding gene, a recombinant vector and an engineering bacterium of the mutant. The mutant not only can be used for efficient bioremediation of salicylic acid pollution, but also can effectively break through and accelerate a naphthalene catabolism pathway due to the characteristic of directionally generating catechol, and has important application value in the fields of environmental pollution abatement and biological catalysis.

The invention relates to the technical field of bioengineering, in particular to a penicillin G acylase mutant, polynucleotide, an expression vector and application. The penicillin G acylase mutant is obtained by carrying out site-directed mutagenesis on a wild type penicillin G acylase gene of parent Escherichia coli, and carrying out site-directed mutagenesis on the wild type penicillin G acylase gene to obtain the penicillin G acylase mutant. Phenylalanine (F) at the 24th site of an alpha chain, proline (P) at the 383rd site of a beta chain, threonine (T) at the 384th site of the beta chain, glutamic acid (G) at the 385th site of the beta chain and serine (S) at the 386th site of the beta chain of the penicillin G acylase are introduced and mutated by a whole plasmid PCR (Polymerase Chain Reaction) technology to obtain mutants. When the penicillin G acylase mutant obtained by the invention is used for catalyzing methyl mandelate and 3-(1-methyl-1H-tetrazole-5-yl) thiomethyl-7-aminocephalosporanic acid to synthesize cefamandole, the synthesis activity is improved, and meanwhile, the side reaction rate is greatly reduced.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The present invention relates to a method of preventing or alleviating the effect of abiotic stress in a plant, which involves applying to the plant, including plant seeds or to a plant growth medium, an effective amount of phenylalanine and / or any salt or solvate thereof and a seaweed extract.

The present specification relates to a composition including a new amide-based compound derived from an amino acid structure such as valine, leucine, phenylalanine, proline, pipecolic acid, or the like, wherein the composition exhibits a skin anti-aging or skin reverse-aging effect by restoring the size and number of dendrites of aged melanin-producing cells to those of young cells. As a result, the composition may exhibit a skin brightening effect by inhibiting the amount of melanin produced in the melanin-producing cells.

The application provides a kind of load exosome composite hydrogel and preparation method thereof, belong to biomaterial and drug delivery technical field;Its preparation method includes: modified chitosan;Modified hyaluronic acid;Preparation of biphasic calcium phosphate nanoparticles;Preparation of composite hydrogel.The application is through nucleophilic ring-opening reaction of 1,2-epoxy butane and the hydroxyl group of chitosan, form hydroxybutyl ether bond, give hydroxybutyl chitosan temperature sensitive characteristics, then, again, after activation 3,4-dihydroxyphenylalanine is condensed with hydroxybutyl chitosan, form amide bond, to graft 3,4-dihydroxyphenylalanine on hydroxybutyl chitosan, after modification of chitosan, 3,4-dihydroxyphenylalanine can form strong adhesion interface with cartilage, synovial membrane and other tissues through hydrogen bond, pi-pi stacking and metal coordination, thereby effectively prolonging the residence time of hydrogel in joint.

The present invention relates to a cosmetic composition, advantageously an eco-biological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the general formula (I) in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an alpha-amino acid chosen from the group consisting of phenylalanine, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The present invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating cutaneous vascular hyperproliferation and / or cutaneous inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combating these pathologies.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

This invention belongs to the field of membrane separation and functional membrane materials technology, and discloses a chiral graphene oxide-based separation membrane, its preparation method, and its application. The membrane is composed of graphene oxide and / or reduced graphene oxide sheets and a single-stranded DNA-single-walled carbon nanotube complex. The single-stranded DNA helically winds around the outer surface of the single-walled carbon nanotubes to form a one-dimensional chiral nanochannel and intercalates between the sheets, forming a three-dimensional chiral channel network connected in the membrane thickness direction. The preparation method includes: heating and decohexing salmon sperm double-stranded DNA in a urea-containing buffer to obtain single-stranded DNA; dispersing single-walled carbon nanotubes and then complexing them with the single-stranded DNA; further mixing with a graphene oxide or reduced graphene oxide dispersion; and vacuum filtration to form the membrane. This membrane exhibits a high separation factor for chiral enantiomers such as L / D-phenylalanine, with an excess value of up to 99.95% for L-phenylalanine enantiomers after multi-stage separation, making it suitable for the efficient separation of chiral drugs and amino acids.

The invention discloses an antifouling elastic sofa fabric and a preparation method thereof, and relates to the technical field of fabrics. Diphenylmethane diisocyanate, polypropylene oxide glycol and modified silicon dioxide are subjected to surface reaction to prepare a nano waterproof finishing agent, and the modified silicon dioxide is prepared by modifying sodium hydroxide, so that the antistatic effect of the fabric can be improved; dL-3-fluorophenylalanine methyl ester hydrochloride is grafted to cotton fibers, fluorine-containing groups of the DL-3-fluorophenylalanine methyl ester hydrochloride are greatly enriched on the surface of the fabric, the low surface energy of the fabric is reduced, stains are prevented from being attached to the surface of the fabric, the antifouling effect is achieved, meanwhile, DL-3-fluorophenylalanine methyl ester hydrochloride can be bonded with the nano waterproof finishing agent, a net-shaped cross-linked structure is formed, and the anti-fouling effect is achieved. The nano waterproof finishing agent is adsorbed into fibers of the fabric, so that the waterproof and antifouling effects of the fabric are further improved. The fabric prepared by the invention has waterproof and antifouling effects.

This invention discloses a method for preparing the DPP1 inhibitor bresocarte, belonging to the field of pharmaceutical synthesis. Specifically, the method includes the following steps: N-tert-butoxycarbonyl-L-4-bromophenylalanine reacts with methanesulfonyl chloride or 4-nitrobenzenesulfonyl chloride in the presence of a base, followed by amination substitution to obtain intermediate 1; then, it undergoes dehydration in the presence of trifluoroacetic anhydride to obtain intermediate 2; next, it undergoes a coupling reaction with pinacol diboronate to obtain intermediate 3; then, it undergoes a coupling reaction with bromide compound 4 to obtain intermediate 5; then, it undergoes cyclization with di-tert-butyl dicarbonate in the presence of sodium methoxide to obtain intermediate 6; then, it undergoes deprotection in the presence of hydrogen chloride to obtain intermediate 7; next, it undergoes condensation with compound 8 to obtain intermediate 9; finally, it undergoes deprotection in the presence of hydrogen chloride to obtain the inhibitor bresocarte. This method provides a new synthetic approach, with low overall cost, simple operation, high yield, and suitability for industrial production.

The invention discloses a pinene synthase mutant and application thereof in pinene production, and belongs to the technical field of bioengineering. Isoleucine at the 409th site of pinene synthase is mutated into valine, phenylalanine at the 443rd site of pinene synthase is mutated into alanine, overexpression is carried out in serratia marcescens (HBQA7), and an engineering strain ST17 is constructed. Under the condition of shake flask fermentation, the pinene yield of the engineering strain ST17 reaches 0.80 g / L; the yield is obviously increased to 43.2 g / L through amplification culture in a 30 L fermentation tank. The invention provides an efficient, economic and environment-friendly novel method for industrial biosynthesis of pinene.

The present invention relates to peptide conjugates that comprise a plant-derived oligopeptide capable of crossing the blood-brain barrier (BBB) and a therapeutic or diagnostic agent. The BBB-penetrating oligopeptide is an oligopeptide according to Formula I, Asp–R2–Gly–Leu–R5–R6–R7–Leu–Gly–R10–R11–R12, wherein R2 represents Arg, Lys, Cyt, D-Arg or Orn; R5 represents Phe, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, Orn, 4-aminophenylalanine or 3-phenylpropionate; R6 represents Pro, Leu, Glu or Lys; R7 represents Phe or Trp; R10, R11 and R12 each independently represent Lys, Arg or Orn; or an oligopeptide according to Formula II, Glu–R2'–R3'–Gly–R5'–R6'–Glu–R8'–R9'–R10'–Glu–R12'–Leu–Pro–Gly, wherein R2', R3', R8', R10' and R12' each independently represent Lys, Arg or Orn; R5' represents Phe, Ile, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, 4-aminophenylalanine, or 3-phenylpropionate; R6' represents Met, Leu, Ile, Asn, norleucin, D-norleucin, seleno- methionine or D / L-2-hydroxy-(4-methylseleno)butanoic acid; and R9' represents Leu or Ile. The conjugates comprising a BBB-penetrating oligopeptide compound and a therapeutic agent can be used in treatments for diseases of the central nervous system (CNS). Furthermore, conjugates with a BBB-penetrating oligopeptide compound and a diagnostic agent can be used in both in vivo and in vitro diagnostic methods.

This invention belongs to the field of biomedical technology and provides a polypeptide with ATG8 protein binding activity, comprising the following structure: X1-X2-X3-X4-X5-X6-X7; wherein: X1, X2, and X3 are independently selected from glutamic acid or are absent; X4 is selected from tryptophan, phenylalanine, or leucine; X5 is valine; X6 is selected from leucine, isoleucine, or valine; and X7 is selected from valine, tryptophan, phenylalanine, or tyrosine. Compared with existing autophagy inhibitors, this polypeptide has the following superior pharmacokinetic potential and development flexibility in terms of target selection, binding strength, and mechanism of action: the short sequence not only reduces synthesis costs but also leaves more room for modification, which is expected to significantly improve the metabolic stability and drug-likeness potential of the polypeptide; it can serve as a highly efficient ATG8 targeting ligand and can be widely used in the construction of biochemical probes, screening of PPI competitive inhibitors, and the development of targeted delivery systems.

The invention relates to a tetrapeptide of formula N-Palmitoyl-Lys-Thr-Phe-Lys, for use in the prevention and / or treatment of human atopic dermatitis (AD), as well as to a composition comprising at least said tetrapeptide and at least one physiologically acceptable excipient, for use in the prevention and / or treatment of human atopic dermatitis (AD).

This application provides a method for preparing pH-responsive polyamino acid drug-loaded nanoparticles based on sarcosine and their application. Sar-NNCA, L-lysine-NCA, and L-phenylalanine-NCA are dissolved in anhydrous DMF and polymerized under argon protection with a hexamethyldisilazine initiator to obtain a polyamino acid block copolymer Sar-NNCA. 80 -Lys(Cbz) n -Phe 10 The crude product was deprotected under HBr / acetic acid and loaded with DOX to obtain Sar. 80 -Lys n -Phe 10 -DOX. This application describes the preparation of a pH-responsive polymer nanoplatform, Sar, by encapsulating doxorubicin in polysarcosine-polylysine-polyphenylalanine nanoparticles via Schiff base bonds. 80 -Lys n -Phe 10 -DOX is used for tumor treatment. These polyamino acid nanoparticles are spherical with an average particle size of approximately 200 nanometers, exhibiting pH-responsive properties, excellent cellular uptake capacity, and anti-tumor effects. In vitro experiments show that Sar... 80 -Lys n -Phe 10 The carrier material exhibits excellent biocompatibility. The newly synthesized Sar... 80 -Lys n -Phe 10 -DOX nanomicelles show promise as a drug delivery system for cancer treatment.

This invention discloses a water-soluble melanin CEST contrast agent, its preparation method, and its application, relating to the field of magnetic resonance imaging contrast agent technology. This contrast agent, its preparation method, and its application aim to solve the technical problem that existing contrast agents containing paramagnetic metals can damage liver and kidney function. This water-soluble melanin CEST contrast agent comprises the following components by weight: 2-3 parts ammonia, 40 parts ethanol, 100 parts deionized water, and 0.5 parts reaction substrate. The chemical shift corresponding to this contrast agent preparation method is 4.0 ppm, exhibiting good adaptability to acidic environments and suitability for use in the tumor microenvironment. It is polymerized using dopamine hydrochloride or 3,4-dihydroxyphenylalanine, with inexpensive, simple, and readily available raw materials, simple synthesis, and easy large-scale preparation. It achieves tumor imaging without the need for paramagnetic metal ions, avoiding the damage to liver and kidney function caused by heavy metal ions.

The present invention relates to crystals of N-(benzoyl)-phenylalanine-based compounds, pharmaceutical compositions thereof, preparation methods and uses. Specifically, as shown in Formula (I) and Formula (II), the crystals of the compound of Formula (I) have crystal form A, and the crystals of the compound of Formula (II) have crystal form B. The two crystal forms have good stability, high reproducibility of the preparation method, high operability, and important application value in the prevention and / or treatment of diseases related to α4β7 integrin. [Chemical formula 1] TIFF2025518346000014.tif44156

The application discloses a preparation method of zolmitriptan, relates to the technical field of drug synthesis, and comprises the following steps: adding compound 1 and reagent 1 into solvent 1 to perform a first reaction to obtain compound 2; adding the compound 2, reagent 2 and reagent 3 into solvent 2 to perform a second reaction to obtain compound 3 and the like. Compared with the prior art, the application provides a novel synthetic route for preparing zolmitriptan, the route uses L-4-bromophenylalanine as a starting material, and new synthetic steps are adopted, such as using reagent 5, such as a t-butyl alcohol metal salt and sodium hydride, to construct the oxazolidinone structure in zolmitriptan and using a coupling reaction to construct the indole ring in zolmitriptan, so that the yield of the obtained target product is significantly improved, the use of high-toxicity and high-risk reagents in the existing synthetic route is effectively avoided, and a mild, efficient, green and environmentally-friendly synthetic route for preparing zolmitriptan is provided.

The application provides a polypeptide vaccine delivery carrier, which is a phenylalanine-based polyester amide polymer prepared from triethylamine, p-nitrophenol, L-phenylalanine and butanediol. + The polypeptide vaccine has good stability, high antigen presentation effect, and can induce the body to produce effective antitumor CD8 T cell immune response, inhibit tumor growth and metastasis, and improve the effect of immunotherapy.

The present application relates to the technical field of synthetic biology, in particular to a multi-module synergistic optimization of brown cyanidin and brevifolin production of saccharomyces cerevisiae engineering bacteria and its construction method and application. The saccharomyces cerevisiae engineering bacteria includes naringenin synthesis pathway, optimization pathway of shikimic acid, synergistic pathway of phenylalanine, 6-OH luteolin synthesis pathway, brown cyanidin and brevifolin synthesis pathway, multiple copies of SbF6H and MpalOMT2, NADPH optimization pathway, and SAM cycle optimization pathway. The saccharomyces cerevisiae engineering bacteria is used for producing brown cyanidin and brevifolin, and improving the yield of the two.

The invention relates to a compound synthesis technology, in particular to a preparation method of 4-boron-L-phenylalanine. The reaction route of the preparation method is shown in the specification. According to the reaction route of the preparation method of the 4-boron-L-phenylalanine provided by the invention, the L-BPA is prepared by utilizing the boron spiro compound provided by the invention, so that the problems that the existing direct synthesis reaction route is relatively long, the reaction condition is harsh, a chiral catalyst is difficult to obtain and the like can be avoided. L-BPA with higher chemical yield is obtained through a shorter reaction route under mild reaction conditions.